clinical therapeutics - Robuta Search

https://www.canberra.edu.au/unit/9402/2/2027 Clinical Therapeutics 3 PG (9402) - University of Canberra clinical therapeutics university of 3 pg 9402 https://www.canberra.edu.au/unit/9403/2/2027 Clinical Therapeutics 4 PG (9403) - University of Canberra clinical therapeutics 4 pg university of 9403 canberra https://www.omicsonline.org/open-access/an-overview-of-encephalopathy-118126.html The Neurologist: Clinical & Therapeutics Journal - An Overview of Encephalopathy -An Overview of Encephalopathy the neurologist clinical therapeutics an overview journal encephalopathy https://www.canberra.edu.au/unit/9010/2/2027 Clinical Therapeutics 4 (9010) - University of Canberra clinical therapeutics university of 4 canberra https://www.biospace.com/avadel-pharmaceuticals-announces-publication-in-clinical-therapeutics-of-data-highlighting-weight-loss-in-people-with-narcolepsy-treated-with-lumryz-sodium-oxybate-extended-release-oral-suspension Avadel Pharmaceuticals Announces Publication in Clinical Therapeutics of Data Highlighting Weight... avadel pharmaceuticals clinical therapeutics announces publication https://www.canberra.edu.au/unit/9401/2/2027 Clinical Therapeutics 2 PG (9401) - University of Canberra clinical therapeutics 2 pg university of 9401 canberra https://clinicalmed.uonbi.ac.ke/ Department of Paediatrics & Child Health | Department of Clinical Medicine and Therapeutics department of paediatrics child health clinical medicine therapeutics https://central.ascpt.org/home Home - American Society For Clinical Pharmacology and Therapeutics american society clinical pharmacology therapeutics https://www.biospace.com/press-releases/allarity-therapeutics-announces-expansion-of-phase-2-clinical-trial-to-accelerate-development-of-stenoparib-in-advanced-ovarian-cancer Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of... phase 2 clinical trial expansion of https://finviz.com/news/151288/marker-therapeutics-mrkr-falls-206-after-positive-clinical-study Marker Therapeutics (MRKR) Falls 20.6% After Positive Clinical Study Stock screener for investors and traders, financial visualizations. 20 6 marker therapeutics falls positive https://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-updated-phase-2-rusfertide-clinical-results-in-polycythemia-vera-pv-at-asco-2022-301556326.html Protagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia... /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) today announced new data from its ongoing Phase 2 REVIVE study evaluating rusfertide in patients with... phase 2 https://www.biospace.com/cerevel-therapeutics-initiates-phase-1b-clinical-trial-of-cvl-231-a-m4-selective-positive-allosteric-modulator-in-development-for-the-treatment-of-schizophrenia Cerevel Therapeutics Initiates Phase 1b Clinical Trial of CVL-231, a M4 Selective Positive... Oct 22, 2019 - Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today it has dosed the first... https://www.prnewswire.com/news-releases/aardvark-therapeutics-aard-faces-investor-scrutiny-amid-56-drop-on-clinical-pause-for-lead-drug-candidate-hagens-berman-302750579.html Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug... /PRNewswire/ - On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company... https://www.biospace.com/press-releases/keros-therapeutics-announces-initial-topline-results-from-the-phase-1-clinical-trial-of-ker-065-in-healthy-volunteers Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in... https://www.prnewswire.com/news-releases/halia-therapeutics-announces-positive-topline-data-and-advances-to-second-stage-of-phase-2-clinical-trial-for-ht-6184-in-patients-with-low-risk-myelodysplastic-syndromes-lr-mds-302325033.html Halia Therapeutics Announces Positive Topline Data and Advances to Second Stage of Phase 2 Clinical... /PRNewswire/ -- Halia Therapeutics, a biopharmaceutical company at the forefront of developing treatments for chronic inflammation and related disorders,... https://www.biospace.com/carrick-therapeutics-and-the-menarini-group-announce-clinical-trial-collaboration-to-evaluate-samuraciclib-and-elacestrant-combination Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate... Dec 19, 2022 - Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, and the Menarini Group... menarini group https://www.biospace.com/menlo-therapeutics-presents-successful-phase-2-clinical-trial-results-of-serlopitant-in-psoriasis-at-the-european-academy-of-dermatology-and-venereology-meeting Menlo Therapeutics Presents Successful Phase 2 Clinical Trial Results of Serlopitant in Psoriasis... Oct 11, 2019 - Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, presented results from its successful Phase 2 clinical trial of serlopitant for... phase 2 clinical trial https://www.wallstreet-online.de/nachricht/20692281-relay-therapeutics-to-present-initial-clinical-data-on-zovegalisib-vascular-anomalies-at-the-international-society-for-the-study-of-vascular-anomalies-world-congress-2026 Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the... 02.04.2026 - CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) - Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine... https://www.biospace.com/isotopia-molecular-imaging-begins-clinical-supply-collaboration-with-y-mabs-therapeutics-inc Isotopia Molecular Imaging begins clinical supply collaboration with Y-mAbs Therapeutics, Inc. -... Nov 5, 2020 - Isotopia Molecular Imaging is pleased to announce that it has begun a collaboration with Y-mAbs Therapeutics, Inc., a late-stage clinical biopharmaceutical... molecular imaging clinical supply https://www.biospace.com/connecta-therapeutics-starts-clinical-trials-for-its-fragile-x-syndrome-drug Connecta Therapeutics starts clinical trials for its Fragile X syndrome drug - BioSpace Jun 6, 2023 - This Phase I clinical trial will assess the safety and tolerability of CTH120, which acts as a neuroplasticity modulator. fragile x syndrome clinical trials https://www.globenewswire.com/news-release/2016/07/18/856862/0/en/Cynapsus-Therapeutics-Provides-European-Clinical-Update-for-APL-130277-for-the-Treatment-of-OFF-Episodes-in-Patients-with-Parkinson-s-Disease.html Cynapsus Therapeutics Provides European Clinical Update for -- Company plans to initiate pivotal program in fourth quarter ---- Webcast with accompanying slides to discuss program tomorrow at 7:30 a.m. Eastern time... cynapsus therapeutics clinical update provides european https://pmc.ncbi.nlm.nih.gov/articles/PMC12030352/ Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical... Peptide and protein (PP) therapeutics are highly specific and potent biomolecules that treat chronic and complex diseases. However, their oral delivery is... https://investingnews.com/nurix-therapeutics-announces-webcast-to-review-new-and-updated-data-from-the-phase-1-clinical-trial-of-btk-degrader-bexobrutideg-to-be-presented-at-the-67th-american-society-of-hematology-annual-meeti/ Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial... Dec 1, 2025 - Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted... https://www.mcgill.ca/study/2024-2025/courses/nur2-623 NUR2 623 Clinical Assessment and Therapeutics 1 (3 credits) | eCalendar - McGill University clinical assessment https://www.wolterskluwer.com/nl-be/solutions/ovid/ocular-therapeutics-handbook--a-clinical-manual-5279 Ovid - Ocular Therapeutics Handbook: A Clinical Manual | Wolters Kluwer Selected as a Doody's Core Title for 2023! Offering concise, easy-access information for the most common ocular problems, Ocular Therapeutics Handbook: A... ovid ocular therapeutics handbook clinical https://www.uchicagomedicine.org/cancer/research/research-programs/clinical-and-experimental-therapeutics Clinical and Experimental Therapeutics - UChicago Medicine The Clinical and Experimental Therapeutics Program is a cohesive, integrated program with a long-standing focus on drug development at all phases of clinical... clinical experimental therapeutics uchicago medicine https://www.prnewswire.com/news-releases/verismo-therapeutics-completes-merger-to-accelerate-clinical-development-302336395.html?tc=eml_cleartime Verismo Therapeutics Completes Merger to Accelerate Clinical Development /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company developing novel KIR-CAR platform technology, today announced the completion of a merger... verismo therapeutics completes merger accelerate https://www.businesswire.com/news/home/20260209315923/en/VectorY-Therapeutics-Announces-First-Participant-Dosed-in-Phase-12-PIONEER-ALS-Clinical-Trial-of-VTx-002-in-People-with-Amyotrophic-Lateral-Sclerosis-ALS?dm_i=40VQ,1RZ6S,73ZN21,710VW,1,0,0,0 VectorY Therapeutics Announces First Participant Dosed in Phase 1/2 PIONEER-ALS Clinical Trial of... VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the first participant has been dosed in ... https://www.biospace.com/bold-therapeutics-presents-jaw-dropping-interim-phase-2-clinical-data-for-bold-100-in-the-treatment-of-advanced-colorectal-cancer-at-aacr-2023 Bold Therapeutics Presents Jaw-Dropping Interim Phase 2 Clinical Data for BOLD-100 in the Treatment... Apr 18, 2023 - Bold Therapeutics announced positive interim results from a Phase 2 clinical trial evaluating BOLD-100 in combination with standard-of-care chemotherapy for... https://www.businesswire.com/news/home/20230323005287/en/GRIN-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1B-Clinical-Trial-with-Radiprodil-for-Treatment-of-GRIN-related-Disorders GRIN Therapeutics Announces First Patient Dosed in Phase 1B Clinical Trial with Radiprodil for... GRIN Therapeutics Inc. Announces First Patient Dosed in Phase 1B Clinical Trial with Radiprodil for Treatment of GRIN-related Disorders. https://www.prnewswire.com/news-releases/aileron-therapeutics-to-present-previously-announced-data-from-the-phase-1b-clinical-trial-evaluating-low-dose-lti-03-in-idiopathic-pulmonary-fibrosis-ipf-at-the-22nd-international-colloquium-on-lung-and-airway-fibrosis-302274268.html Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial... /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to... https://www.businesswire.com/news/home/20221106005001/en/Apros-Therapeutics-to-Present-Interim-Clinical-Data-from-a-Phase-1-Study-Evaluating-APR003-at-the-2022-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting-and-World-Vaccine-Immunotherapy-Congress-WVIC-West-Coast Apros Therapeutics to Present Interim Clinical Data from a Phase 1 Study Evaluating APR003 at the... Apros Therapeutics, Inc., a clinical stage biotechnology company focused on tissue-targeted Toll-Like Receptor 7 (TLR7) agonists for the treatment of advance... https://www.businesswire.com/news/home/20240327454257/en/Aldeyra-Therapeutics-Announces-Clinical-Development-Plan-for-Resubmission-of-New-Drug-Application-for-Reproxalap-in-Dry-Eye-Disease Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application... Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat imm... clinical development https://www.prnewswire.com/news-releases/nested-therapeutics-reports-initial-encouraging-clinical-activity-and-favorable-tolerability-of-nst-628-a-brain-penetrant-pan-rafmek-molecular-glue-at-aacr-2026-302746186.html Nested Therapeutics Reports Initial Encouraging Clinical Activity and Favorable Tolerability of... /PRNewswire/ -- Nested Therapeutics, a clinical-stage oncology company developing transformative therapies for RAS/MAPK-driven disorders, today reported... clinical activity nested therapeutics reports initial https://www.uh.edu/uh-energy-innovation/news-events/innovation/stories/2025/indaptastory.php UH Tech Bridge Community Member Indapta Therapeutics Advances Clinical Trials with $22.5M Funding |... UH Tech Bridge member Indapta Therapeutics has secured $22.5 million to advance clinical trials of its lead g-NK cell therapy, IDP-023, for cancer and... https://www.businesswire.com/news/home/20210302005028/en/Pipeline-Therapeutics-Initiates-Phase-1-Clinical-Trial-of-PIPE-307 Pipeline Therapeutics Initiates Phase 1 Clinical Trial of PIPE-307 Pipeline Therapeutics Initiates Phase 1 Clinical Trial of PIPE-307 phase 1 clinical trial pipeline therapeutics initiates 307 https://www.prnewswire.co.uk/news-releases/modus-therapeutics-announces-new-strategy-for-the-clinical-development-of-sevuparin-as-a-potential-treatment-for-sepsis-septic-shock-816240494.html Modus Therapeutics Announces New Strategy for the Clinical Development of Sevuparin as a Potential... /PRNewswire/ -- Modus Therapeutics AB, a company developing innovative treatments for patients with high unmet medical needs, announces an updated strategy... https://www.biospace.com/vitrac-therapeutics-to-present-phase-1-clinical-trial-design-on-novel-aurora-kinase-a-inhibitor-vic-1911-and-g12c-inhibitor-sotorasib-for-kras-g12c-mutant-non-small-cell-lung-cancer-at-the-2023-asco-annual-meeting VITRAC Therapeutics to Present Phase 1 Clinical Trial Design on Novel Aurora Kinase A Inhibitor,... Jun 5, 2023 - VITRAC Therapeutics, LLC presented a poster on the Phase 1a/1b clinical trial of aurora kinase A inhibitor, VIC-1911, as monotherapy and in combination with... phase 1 clinical trial https://www.biospace.com/transcode-therapeutics-reports-positive-pre-clinical-results-in-metastatic-pancreatic-cancer-with-its-lead-candidate-ttx-mc138ttx-mc138-is-effective-in-animal-models-of-human-metastatic-pancreatic-cancer TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with... Dec 12, 2023 - TransCode Therapeutics, Inc. today reported successful completion of a preclinical study comprising four independent replicates with its lead therapeutic... clinical results https://www.biospace.com/kymera-therapeutics-to-present-new-clinical-data-from-the-ongoing-phase-1-trial-of-stat3-degrader-kt-333-at-eha-annual-meeting Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader... May 15, 2024 - Kymera Therapeutics, Inc. announced that new Phase 1 data for KT-333, a first-in-class degrader of STAT3, highlighting safety, pharmacokinetics,... https://www.biospace.com/vistagen-therapeutics-announces-last-patient-completes-dosing-in-the-elevate-phase-2-clinical-study-of-av-101-for-major-depressive-disorder VistaGen Therapeutics Announces Last Patient Completes Dosing in the ELEVATE Phase 2 Clinical Study... Oct 9, 2019 - VistaGen Therapeutics announced that the last patient has completed dosing in the ELEVATE Phase 2 clinical study of AV-101, the Company's novel, oral NMDA... https://www.biospace.com/f-star-therapeutics-announces-first-patient-dosed-in-fs222-phase-1-clinical-trial F-star Therapeutics Announces First Patient Dosed in FS222 Phase 1 Clinical Trial - BioSpace Jan 4, 2021 - F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the... phase 1 clinical trial https://investingnews.com/nurix-therapeutics-presents-new-translational-data-from-first-in-human-clinical-trial-of-oral-cbl-b-inhibitor-nx-1607-demonstrating-immune-activation-and-tumor-microenvironment-remodeling/ Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B... Nov 7, 2025 - Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies to treat cancer and immune... https://www.biospace.com/relmada-therapeutics-announces-filing-of-clinical-trial-application-in-canada-for-novel-oral-formulations-of-buprenorphine Relmada Therapeutics Announces Filing Of Clinical Trial Application In Canada For Novel Oral... https://www.biospace.com/capricor-therapeutics-inc-completes-enrollment-of-phase-ii-clinical-trial-for-cenderitide-to-treat-heart-failure Capricor Therapeutics, Inc. Completes Enrollment Of Phase II Clinical Trial For Cenderitide To... phase ii clinical trial https://www.biospace.com/press-releases/guided-therapeutics-provides-update-on-completion-of-us-fda-clinical-trial Guided Therapeutics Provides Update on Completion of US FDA Clinical Trial - BioSpace https://www.prnewswire.com/news-releases/nektar-therapeutics-announces-completion-of-target-enrollment-in-rezolve-aa-phase-2b-clinical-trial-of-rezpegaldesleukin-in-patients-with-severe-to-very-severe-alopecia-areata-302385779.html Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial... /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AA Phase 2b study of... https://www.biospace.com/dyne-therapeutics-announces-submission-of-ind-application-to-initiate-clinical-trial-of-dyne-251-for-duchenne-muscular-dystrophy Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251... Dec 2, 2021 - Dyne Therapeutics, Inc. (Nasdaq: DYN), today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration... ind application https://www.newswire.ca/news-releases/transition-therapeutics-announces-results-from-phase-1-ame--renal-clearance-clinical-studies-of-neuropsychiatric-drug-candidate-elnd005-517399091.html Transition Therapeutics Announces Results from Phase 1 AME & Renal Clearance Clinical Studies of... /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX:TTH) today announced results from two phase 1 clinical studies of... https://www.biospace.com/adc-therapeutics-announces-first-patient-dosed-in-pivotal-phase-2-portion-of-lotis-3-clinical-trial-of-loncastuximab-tesirine-lonca-in-combination-with-ibrutinib ADC Therapeutics Announces First Patient Dosed in Pivotal Phase 2 Portion of LOTIS 3 Clinical Trial... Jul 17, 2020 - Combination is being evaluated in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL) https://clinicaltrials.ptcbio.com/ Welcome to PTC Therapeutics Clinical Trials Education and Information about participating in a PTC Therapeutics clinical trial. welcome to ptc therapeutics clinical trials https://www.biospace.com/axial-therapeutics-announces-completion-of-enrollment-in-global-phase-2b-clinical-trial-for-ab-2004-for-irritability-associated-with-autism Axial Therapeutics Announces Completion of Enrollment in Global Phase 2b Clinical Trial for AB-2004... Sep 26, 2023 - Axial Therapeutics today announced completion of enrollment in the TAPESTRY Autism Study, the Phase 2b clinical trial of its lead product candidate, AB-2004, a... https://www.omicsonline.org/guidelines-neurologist-clinical-therapeutics-journal.php Guidelines about The Neurologist: Clinical and Therapeutics Journal The editor in chief of The Neurologist: Clinical and Therapeutics Journal journal issues guidelines to the reviewers, authors, and editors for receiving,... about the guidelines neurologist clinical therapeutics https://www.roche.com/investors/updates/inv-update-2020-07-13c Spark Therapeutics Announces Updated Data on SPK-8011 from Phase 1/2 Clinical Trial in Hemophilia A... Dear Investor, Please find attached a press release by Spark Therapeutics: https://sparktx.com/press_releases/isth2020/ Do not hesitate to contact us for any... https://stockhouse.com/news/press-releases/2018/12/20/proteostasis-therapeutics-provides-clinical-enrollment-update 2018-12-20 | Proteostasis Therapeutics Provides Clinical Enrollment Update | Press Release (2018-12-20) Proteostasis Therapeutics Provides Clinical Enrollment Update 2018 12 proteostasis therapeutics https://www.businesswire.com/news/home/20251209988664/en/Ventus-Therapeutics-Announces-First-Patient-Dosed-in-Phase-2-Clinical-Trial-of-VENT-03-a-Novel-Small-Molecule-cGAS-Inhibitor-in-Patients-with-Lupus Ventus Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of VENT-03, a Novel... Ventus Therapeutics, a clinical-stage biopharmaceutical company advancing multiple small-molecule programs for immunological, inflammatory, and neurological ... https://www.prnewswire.com/news-releases/seelos-therapeutics-provides-second-quarter-2023-clinical-update-301899707.html Seelos Therapeutics Provides Second Quarter 2023 Clinical Update - Seelos expects to release top-line data in its registration directed study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and... second quarter seelos therapeutics provides 2023 https://www.biospace.com/dyne-therapeutics-announces-positive-initial-clinical-data-from-achieve-trial-in-dm1-patients-and-deliver-trial-in-dmd-patients-demonstrating-promise-of-the-force-platform-in-developing-therapeutics-for-rare-muscle-diseases Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and... Jan 4, 2024 - Dyne Therapeutics, Inc. announced positive initial clinical data from its ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 and its DELIVER... https://regor.com/ Pre-clinical target discovery, validation, and optimization - Regor Therapeutics Group Jan 8, 2026 - Regor combines a cutting-edge drug discovery engine with target validation and optimization for preclinical candidates in metabolism, oncology, and immunology target discovery pre clinical validation optimization https://www.businesswire.com/news/home/20230718150286/en/Secretome-Therapeutics-Appoints-Margot-Connor-as-Board-Director-and-Assembles-World-Class-Clinical-Advisory-Board Secretome Therapeutics Appoints Margot Connor as Board Director and Assembles World-Class Clinical... Secretome Therapeutics, a biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells (nMSC) today announced the appoin... https://www.biospace.com/press-releases/pliant-therapeutics-presents-clinical-and-preclinical-data-at-the-american-thoracic-society-international-conference Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society... https://www.biospace.com/mission-therapeutics-strengthens-clinical-development-team-with-appointment-of-dr-judit-molnar-as-senior-director-translational-medicine Mission Therapeutics Strengthens Clinical Development Team with Appointment of Dr Judit Molnar as... Sep 10, 2018 - Mission Therapeutics today announced the appointment of Dr Judit Molnar, MD, PhD to Senior Director of Translational Medicine with immediate effect. https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-first-patient-dosed-in-clinical-study-of-tegavivint-a-first-in-class-wnt-catenin-inhibitor-in-relapsedrefractory-osteosarcoma-302683289.html Iterion Therapeutics Announces First Patient Dosed in Clinical Study of Tegavivint, a... /PRNewswire/ -- Iterion Therapeutics, a clinical-stage, biopharmaceutical company dedicated to revolutionizing the treatment of Wnt-driven cancers, today... https://www.biospace.com/chemomab-therapeutics-announces-new-publications-reinforcing-the-clinical-potential-of-its-ccl24-neutralizing-antibody-cm-101-in-primary-sclerosing-cholangitis Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its... Jun 18, 2024 - Chemomab Therapeutics Ltd. today announced a new scientific publication that further confirms the important role of the soluble protein CCL24 in the... new publications therapeutics announces https://www.prnewswire.com/news-releases/gyala-therapeutics-initiates-phase-iiia-clinical-trial-of-a-car-t-cell-therapy-in-acute-leukemias-with-limited-treatment-options-302681392.html Gyala Therapeutics initiates Phase I/IIa clinical trial of a CAR-T cell therapy in acute leukemias... /PRNewswire/ -- Gyala Therapeutics, a clinical-stage biotechnology company developing innovative cell therapies for hematologic malignancies, today announced... https://www.hiroshima-u.ac.jp/en/activities/researcher/DP_DR/YamazakiYu Distinguished Researcher Yu Yamazaki, Department of Clinical Neuroscience and Therapeutics at the... department of https://www.biospace.com/cell-therapeutics-inc-temporarily-suspends-enrollment-on-pioneer-lung-cancer-clinical-trial-current-patients-continue-to-be-treated Cell Therapeutics, Inc. Temporarily Suspends Enrollment On PIONEER Lung Cancer Clinical Trial;... https://www.biospace.com/neurosense-therapeutics-announces-continuation-of-positive-trends-in-clinical-study-in-als NeuroSense Therapeutics Announces Continuation of Positive Trends in Clinical Study in ALS -... Nov 18, 2020 - Following 9-months of treatment with PrimeC, NeuroSense's combination drug, positive trends first seen in the 6-month interim analysis persist, indicating... positive trends clinical study therapeutics announces continuation https://www.businesswire.com/news/home/20241116643792/en/Encora-Therapeutics-Successfully-Completes-ULTRE-Clinical-Trial-Evaluating-Novel-Wrist-Worn-Wearable-for-Essential-Tremor Encora Therapeutics Successfully Completes ULTRE Clinical Trial Evaluating Novel Wrist-Worn... Encora Therapeutics is pleased to announce the successful completion of the ULTRE (Upper Limb Tremor Reduction in Essential Tremor) clinical trial. This stud... clinical trial therapeutics successfully completes ultre https://www.biospace.com/adc-therapeutics-announces-first-patient-dosed-in-phase-i-clinical-trial-of-adct-601-in-advanced-solid-tumors ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced... Jan 17, 2019 - Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors https://www.skyhawktx.com/ Skyhawk Therapeutics | clinical-stage biotechnology company Skyhawk Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel small molecule therapies designed to modulate... skyhawk therapeutics clinical stage biotechnology https://www.biospace.com/flare-therapeutics-to-present-new-translational-data-in-support-of-clinical-candidate-fx-909-s-phase-1-development-at-sitc-2023-annual-meeting Flare Therapeutics to Present New Translational Data in Support of Clinical Candidate FX-909's... Oct 31, 2023 - Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases,... https://www.biospace.com/fate-therapeutics-announces-clinical-safety-and-activity-data-of-first-ever-ipsc-derived-car-t-cell-therapy-at-2022-ash-annual-meeting Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell... Dec 12, 2022 - Fate Therapeutics, Inc. presented interim clinical data from the dose-escalation stage of its ongoing Phase 1 study of FT819 for patients with relapsed /... https://www.businesswire.com/news/home/20230117005134/en/Indapta-Therapeutics-Names-Moya-Daniels-Senior-Vice-President-of-Regulatory-Quality-and-Clinical-Operations Indapta Therapeutics Names Moya Daniels, Senior Vice President of Regulatory, Quality and Clinical... Indapta Therapeutics Names Moya Daniels, Senior Vice President of Regulatory, Quality and Clinical Operations senior vice president https://www.businesswire.com/news/home/20230918920134/en/FDA-Notifies-Osmol-Therapeutics-that-the-First-in-Human-Phase-1-Clinical-Trial-of-OSM-0205-for-the-Prevention-of-Chemotherapy-induced-Peripheral-Neuropathy-CIPN-May-Proceed FDA Notifies Osmol Therapeutics that the First-in-Human Phase 1 Clinical Trial of OSM-0205 for the... Osmol Therapeutics, a privately held biopharmaceutical company focused on developing a treatment to prevent chemotherapy-induced peripheral neuropathy (CIPN)... https://www.biospace.com/autolus-therapeutics-announces-conference-call-to-review-clinical-data-for-programmed-t-cell-therapy-pipeline-presented-at-the-2019-ash-annual-meeting Autolus Therapeutics Announces Conference Call to Review Clinical Data for Programmed T Cell... Dec 6, 2019 - Autolus Therapeutics plc announced that management will host a conference call and webcast on Monday, December 9, 2019 at 8:30 am ET / 1:30 pm GMT to review... https://www.businesswire.com/news/home/20210208005894/en/Turn-Therapeutics-Announces-First-Subjects-Enrolled-in-Human-Clinical-Trial-for-the-Treatment-and-Prevention-of-COVID-19 Turn Therapeutics Announces First Subjects Enrolled in Human Clinical Trial for the Treatment and... Turn Therapeutics, a biotechnology company specializing in advanced wound care and infection control, today announced enrollment of the first subjects in its... https://finviz.com/news/337382/monte-rosa-therapeutics-announces-clinical-supply-agreement-to-support-phase-2-trial-evaluating-mrt-2359-in-combination-with-apalutamide-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating... Stock screener for investors and traders, financial visualizations. https://coiledplc.com/ Coiled Therapeutics plc | Clinical Stage Oncology Company Coiled Therapeutics is a clinical-stage precision oncology company advancing first-in-class TACC3 inhibitors. Listed on London Stock Exchange AIM market. coiled therapeutics plc clinical stage https://www.biospace.com/press-releases/nektar-therapeutics-announces-completion-of-target-enrollment-in-rezolve-ad-phase-2b-clinical-trial-of-rezpegaldesleukin-in-patients-with-moderate-to-severe-atopic-dermatitis Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial... https://www.uonbi.ac.ke/content/project-driver-ndovu-studydepartment-clinical-medicine-and-therapeutics PROJECT DRIVER, NDOVU STUDY,DEPARTMENT OF CLINICAL MEDICINE AND THERAPEUTICS | University of Nairobi project driver department of https://www.businesswire.com/news/home/20240401099571/en/Clinical-Collaboration-Agreement-between-Teva-and-Launch-Therapeutics-to-Accelerate-Development-of-Dual-Action-Asthma-Rescue-Inhaler-ICS-SABATEV-248-Respiratory-Program-Teva-and-Abingworth-Enter-Strategic-Development-Funding-Agreement Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of... Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Launch Therapeutics, Inc., today announced a clinical collaboration agreement to further accele... clinical collaboration https://www.prnewswire.com/news-releases/lupus-therapeutics-the-clinical-affiliate-of-the-lupus-research-alliance-broadens-proven-peer-to-peer-program-in-clinical-trials-302695041.html Lupus Therapeutics, the Clinical Affiliate of the Lupus Research Alliance, Broadens Proven... /PRNewswire/ -- Today, Lupus Therapeutics, the clinical affiliate of the Lupus Research Alliance, announced the expansion of its proven peer-to-peer clinical... research alliance lupus therapeutics clinical affiliate https://www.wolterskluwer.com/vi-vn/solutions/ovid/ocular-therapeutics-handbook--a-clinical-manual-5279 Ovid - Ocular Therapeutics Handbook: A Clinical Manual | Wolters Kluwer Selected as a Doody's Core Title for 2023! Offering concise, easy-access information for the most common ocular problems, Ocular Therapeutics Handbook: A... ovid ocular therapeutics handbook clinical https://www.businesswire.com/news/home/20200820005861/en/Audentes-Therapeutics-Provides-Update-on-the-ASPIRO-Clinical-Trial-Evaluating-AT132-in-Patients-with-X-linked-Myotubular-Myopathy Audentes Therapeutics Provides Update on the ASPIRO Clinical Trial Evaluating AT132 in Patients... Audentes Therapeutics, Inc., an Astellas company, today announced that a third study patient has passed away in the ASPIRO clinical trial evaluating AT132 in... https://investingnews.com/seelos-therapeutics-announces-year-end-2021-business-and-clinical-update/ Seelos Therapeutics Announces Year-End 2021 Business and Clinical Update | INN Mar 7, 2022 - Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system... year end clinical update seelos therapeutics announces https://www.biospace.com/starton-therapeutics-strengthens-clinical-development-strategy-following-successful-scientific-advisory-board-meeting-at-asco-2024 Starton Therapeutics Strengthens Clinical Development Strategy Following Successful Scientific... clinical development strategy therapeutics following successful scientific https://iat.care/ Integrity Advanced Therapeutics | Clinical Research Houston TX - Integrity Mar 20, 2026 - About Integrity Advanced Therapeutics Advancing Research in Gastroenterology and Liver Disease Integrity Advanced Therapeutics (IAT) is a premier clinical... advanced therapeutics clinical research integrity houston tx https://www.news-medical.net/news/20140408/MicroBiome-Therapeutics-to-present-clinical-trial-data-of-NM504-in-type-2-diabetes-prediabetes-at-ICEENDO-2014.aspx MicroBiome Therapeutics to present clinical trial data of NM504 in type 2 diabetes, prediabetes at... Apr 8, 2014 - MicroBiome Therapeutics LLC, today announced that data from the company's clinical trial of microbiome modulator NM504 in development for type 2 diabetes and... https://www.globenewswire.com/news-release/2025/05/18/3083535/0/en/Applied-Therapeutics-Presents-Full-12-Month-Clinical-Results-and-New-Topline-Data-from-INSPIRE-Phase-2-3-Trial-of-Govorestat-in-CMT-SORD-in-Late-Breaking-Oral-Presentation-at-the-P.html Applied Therapeutics Presents Full 12-Month Clinical Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months ... 12 month applied therapeutics presents full https://www.businesswire.com/news/home/20251111185634/en/Odyssey-Therapeutics-Appoints-Dennis-Dean-Ph.D.-as-Executive-Vice-President-Head-of-Non-Clinical-Development Odyssey Therapeutics Appoints Dennis Dean, Ph.D., as Executive Vice President, Head of Non-Clinical... Dennis Dean, Ph.D., appointed as Executive Vice President and Head of Non-Clinical Development at Odyssey Therapeutics. https://investingnews.com/daily/life-science-investing/biotech-investing/aprea-therapeutics-presents-data-from-phase-1b2-clinical-trial-of-apr-246/ Aprea Therapeutics Presents Data from Phase 1b/2 Clinical Trial of APR-246 | INN Jan 2, 2026 - Aprea Therapeutics (NASDAQ:APRE) has announced preliminary results of its French Phase 1b/2 clinical trial of APR-246 in mutant myelodysplastic syndromes (MDS)... https://www.omicsonline.org/ArchiveNCTJ/articleinpress-neurologist-clinical-therapeutics-journal.php Articles in Press -The Neurologist: Clinical and Therapeutics Journal| OMICS International Articles in the press indicates the manuscripts that have completed the review process and ready for publication in the forthcoming issues of The Neurologist:... articles in press the neurologist https://www.fiercebiotech.com/biotech/lam-therapeutics-closes-40m-financing-and-announces-two-clinical-stage-programs-rare LAM Therapeutics Closes $40M in Financing and Announces Two Clinical-Stage Programs in Rare... Feb 3, 2016 - Bringing the Total Raised for the Current Class of 4Catalyzer Companies to a Quarter-Billion Dollars GUILFORD, CT--(Marketwired - February 03, 2016) - LAM... https://www.crismtherapeutics.com/ CRISM Therapeutics | clinical-stage biotechnology | LSE: CRTX Mar 11, 2026 - Explore the latest advancements in CRISM Therapeutics and their impact on treatment options in modern medicine. crism therapeutics clinical stage biotechnology https://www.biospace.com/press-releases/neumora-therapeutics-announces-initiation-of-phase-1-clinical-study-of-m4-positive-allosteric-modulator-nmra-861 Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric... phase 1 https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-removal-of-fda-clinical-hold-on-the-rusfertide-clinical-development-program-301396885.html Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical... /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that the U.S. Food and Drug Administration... clinical hold on the protagonist therapeutics announces